Canakinumab treatment caused a small but statistically significant reduction in cardiovascular events and thus demonstrated that anti-inflammatory agents and targeting of the NLRP3 inflammasome [38, 39] could reduce the risk of atherosclerotic cardiovascular disease (ASCVD) events [40]. This evidence concerns the gene NLRP3 and atherosclerosis.